exercising on semaglutide Lifestyle Tips for Results — INTRA|V If You're on a GLP-1,

Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine 104-week trial in 3,297 high-risk T2DM patients showed semaglutide reduced composite MACE by 26% versus placebo establishing cardiovascular benefit for GLP-1 receptor agonists

In comparison, the injectable version of Wegovy led to an average weight loss of 15% of body weight after 68 weeks in a previous study, according to the company

The economic calculus changes if insurance does not cover brand-name semaglutide

Through its effects on appetite, digestion, and blood sugar control, it allows patients to achieve meaningful weight loss in a safe and controlled way